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Abstract
Methamphetamine is known to cause a cardiomyopathy which may be reversible with appropriate
medical therapy and cessation of use. Late gadolinium enhancement cardiovascular magnetic
resonance (CMR) has been shown to identify fibrosis in ischemic and non-ischemic
cardiomyopathies. We present a case of severe methamphetamine-associated cardiomyopathy in
which cardiac function recovered after 6 months. Evaluation by CMR using late gadolinium
enhancement was notable for an absence of enhancement, suggesting an absence of irreversible
myocyte injury and a good prognosis. CMR may be useful to predict recovery in toxin-associated
non-ischemic cardiomyopathies.
Background
Methamphetamine is a synthetic amine commonly used
as a recreational drug because of its stimulant effects. Its
use has increased nationwide [1] and recent reports sug-
gest that methamphetamine use is present in at least 5%
of all patients presenting to the emergency room with
heart failure [2] and 40% of patients under the age of 45
admitted to the hospital with cardiomyopathy [3].
Chronic use has also been associated with the develop-
ment of chronic coronary disease [4,5] as well as cardio-
myopathy [3,6].
Recovery of left ventricular dysfunction in patients with
methamphetamine-induced cardiomyopathy has been
described [7-9]. However, since the effects of metham-
phetamine can include myocyte hypertrophy [10] and
fibrosis [11,12], both relatively irreversible processes, it is
likely that some patients will not recover left ventricular
function with either appropriate medical therapy or absti-
nence from methamphetamine.
Cardiovascular magnetic resonance (CMR) with late
gadolinium enhancement (LGE) has been show to iden-
tify myocardial fibrosis in ischemic and non-ischemic car-
diomyopathies [13,14] and provide prognostic
information about cardiac recovery in these disease proc-
esses [15]. LGE has not, to our knowledge, been used to
evaluate fibrosis and predict recovery in methampheta-
mine-associated cardiomyopathy.
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We herein report a case of recovery of left ventricular func-
tion in a patient with methamphetamine-associated cardi-
omyopathy demonstrated using LGE.
Case report
A 44 year old woman presented to the emergency depart-
ment with 3 days of peripheral edema, paroxysmal noc-
turnal dyspnea, and dyspnea on exertion. She denied
chest pain, fever, rashes and/or recent viral illnesses. She
had no recent exposure to ill contacts or foreign travel.
Her review of systems was otherwise unremarkable. Her
past medical history consisted of pregnancy related hyper-
tension 4 years prior that required no therapy after deliv-
ery. Her social history consisted of 15 years of inhaled
methamphetamine and tobacco use. She denied alcohol
or other street drug use. She was taking no medications at
time of presentation. Her surgical history consisted of one
normal child delivery 4 years prior, a tubal ligation and
tonsillectomy. Physical examination revealed a blood
pressure of 159/109 mmHg, pulse of 109 bpm, and a tem-
perature of 36.3°C. Her arterial O2 saturation was 99% on
room air. Cardiac examination revealed a JVP of 12 cm
and a 3/6 holosystolic murmur best heard at the apex
without respiratory variation. She had no organomegaly
or ascites and her extremities had 2+ pitting edema. Her
laboratory data demonstrated a sodium of 138 mEq/L,
creatinine of 1.1, and serum troponin of 0.11 (ng/ml). A
chest X-ray showed cardiomegaly, an electrocardiogram
showed left ventricular hypertrophy and ST-T wave abnor-
malities. Two-dimensional echocardiography showed
reduced systolic function (Figure 1).
After informed consent, she underwent LGE using stand-
ard techniques [16]. Briefly, images were acquired on a
Siemens 3T Trio MR system using a 4 element cardiac
array coil. After localization scans, CINE sequences were
run in three planes for assessment of wall motion and
ejection fraction. The contrast agent (gadolinium-DTPA,
0.2 ml/Kg) was injected and a set of inversion recovery
(IR) gradient recalled echo (GRE) sequences was run with
different TI values starting 5 min after injection. Following
determination of the optimal TI value, IR-GRE "delayed
enhancement" images were acquired in the short axis, ver-
tical long axis and horizontal long axis orientations 10-20
minutes after the injection of the contrast agents. One to
eight slice locations were acquired for each orientation.
Images were analyzed in duplicate using a Leonardo
workstation (Siemens Medical Solutions, Erlangen, Ger-
many). Ejection fraction and left ventricular mass were
calculated by computer-assisted endocardial border defi-
nition of end-diastolic and end-systolic frames. The pres-
ence of gadolinium enhancement was defined as pixel
intensity in the myocardium > 3× background [16].
Echocardiography and CMR both showed a reduced ejec-
tion fraction, calculated at 37% using quantitative analy-
Chest X-ray, electrocardiogram, and 2-D echocardiograms of the patient on initial evaluation Figure 1
Chest X-ray, electrocardiogram, and 2-D echocardiograms of the patient on initial evaluation. These examina-
tions demonstrated cardiomegaly, left ventricular hypertrophy with ST-T wave changes, and decreased left ventricular systolic 
function.Journal of Cardiovascular Magnetic Resonance 2009, 11:46 http://www.jcmr-online.com/content/11/1/46
Page 3 of 5
(page number not for citation purposes)
sis of GRE images. There was no LGE (Figure 2). She was
placed on medical therapy including a beta-blockers and
an angiotensin converting enzyme inhibitor and was
advised to abstain from methamphetamine use.
Following 6 months of medical therapy and decreased use
of methamphetamine, she again was evaluated for signs
and symptoms of heart failure. At this time, she had
improved clinically to functional class I. Echocardiogra-
phy showed a normal ejection fraction and quantitative
CMR showed an ejection fraction of 64% (Figure 3). Left
ventricular mass changed from 234 to 185 grams.
Discussion
This patient illustrates the potential use of LGE as a tool to
predict whether patients with methamphetamine-associ-
ated cardiomyopathy can recover left ventricular function
with appropriate medical therapy. In this instance, the
absence of gadolinium enhancement was consistent with
an absence of macroscopic regions of fibrosis and hence,
no irreversible myocardial injury.
Methamphetamine is a sympathomimetic agent that
mediates its cardiovascular effects through excessive
release of norepinephrine and blockade of reuptake at the
sympathetic synaptic receptors [17]. This sympathetic
stimulation can cause either acute ventricular dysfunc-
tion, such as seen in Takotsubo syndrome [18], or chronic
left ventricular dysfunction [9]. Components of left ven-
tricular dysfunction include both reversible events such as
myocardial stunning [19] and irreversible changes includ-
ing myocyte loss and replacement fibrosis [11]. Animal
studies with 12 week exposure to methamphetamine have
not only shown cellular changes such as atrophy, hyper-
trophy, patchy cellular infiltration, and fibrosis, but have
also demonstrated gradual recovery starting 3 weeks after
cessation of exposure [11]. In patients, there are isolated
case reports suggesting that methamphetamine associated
cardiomyopathy is reversible with discontinuation of
abuse [8,9].
While the extent of fibrosis defined by LGE predicts recov-
ery of left ventricular function in patients with coronary
artery disease and myocardial infarction [16], there are
insufficient data regarding functional recovery in patients
with non-ischemic cardiomyopathy [20]. However, the
extent of fibrosis in patients with non-ischemic cardiomy-
opathy, as identified by LGE, predicts event free survival
[15].
Conclusion
In the specific case of this patient with methampheta-
mine-associated cardiomyopathy, the LGE study did not
demonstrate any enhancement, consistent with an
absence of significant fibrosis. Left ventricular function
recovered with 6 months of medical therapy and
decreased drug abuse. While it is unknown whether, in a
larger cohort of patients, the absence or presence of CMR
identified fibrosis would predict recovery, the benign LGE
findings in this patient likely portended a favorable out-
come.
Late gadolinium enhancement short-axis and vertical long  axis images Figure 2
Late gadolinium enhancement short-axis and vertical 
long axis images. There was no myocardial enhancement 
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